Literature DB >> 1418776

Development of HIV-1 group-specific neutralizing antibodies after seroconversion.

A McKnight1, P R Clapham, J Goudsmit, R Cheingsong-Popov, J N Weber, R A Weiss.   

Abstract

OBJECTIVE: To study the induction of group-specific (gs) neutralizing antibodies to HIV-1 after seroconversion. DESIGN AND METHODS: Serum samples taken sequentially from seven Dutch homosexual men and four British haemophiliacs (anonymous sample, therefore sex not known) before and after seroconversion were tested for neutralizing antibodies effective against five diverse HIV-1 strains. Strains of HIV-1 tested included isolates from the United States, Europe and Africa.
RESULTS: The gs neutralizing antibody response varied between individuals. Only five of the 11 individuals studied produced detectable neutralizing antibodies to laboratory-adapted HIV-1 strains (for example, IIIB) within 32 weeks of seroconversion. Most individuals initially produced antibodies effective against US/European isolates; the response then generally broadened to include the more diverse strains, i.e., African.
CONCLUSIONS: These results suggest that the gs neutralizing target for HIV-1 is poorly immunogenic in vivo and is probably not highly conserved among diverse HIV-1 strains.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1418776     DOI: 10.1097/00002030-199208000-00005

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  11 in total

1.  A human immunodeficiency virus prime-boost immunization regimen in humans induces antibodies that show interclade cross-reactivity and neutralize several X4-, R5-, and dualtropic clade B and C primary isolates.

Authors:  F Verrier; S Burda; R Belshe; A M Duliege; J L Excler; M Klein; S Zolla-Pazner
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

2.  Resistance of a human serum-selected human immunodeficiency virus type 1 escape mutant to neutralization by CD4 binding site monoclonal antibodies is conferred by a single amino acid change in gp120.

Authors:  J A McKeating; J Bennett; S Zolla-Pazner; M Schutten; S Ashelford; A L Brown; P Balfe
Journal:  J Virol       Date:  1993-09       Impact factor: 5.103

3.  Primary virus envelope cross-reactivity of the broadening neutralizing antibody response during early chronic human immunodeficiency virus type 1 infection.

Authors:  P F Zhang; X Chen; D W Fu; J B Margolick; G V Quinnan
Journal:  J Virol       Date:  1999-06       Impact factor: 5.103

4.  Evidence for similar recognition of the conserved neutralization epitopes of human immunodeficiency virus type 1 envelope gp120 in humans and macaques.

Authors:  S E Malenbaum; D Yang; C Cheng-Mayer
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

5.  Detection of antibody-dependent complement-mediated inactivation of both autologous and heterologous virus in primary human immunodeficiency virus type 1 infection.

Authors:  Marlén M I Aasa-Chapman; Sophie Holuigue; Keith Aubin; Mailee Wong; Nicola A Jones; David Cornforth; Pierre Pellegrino; Philippa Newton; Ian Williams; Persephone Borrow; Aine McKnight
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

6.  Characterization of neutralizing monoclonal antibodies to linear and conformation-dependent epitopes within the first and second variable domains of human immunodeficiency virus type 1 gp120.

Authors:  J A McKeating; C Shotton; J Cordell; S Graham; P Balfe; N Sullivan; M Charles; M Page; A Bolmstedt; S Olofsson
Journal:  J Virol       Date:  1993-08       Impact factor: 5.103

7.  Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome.

Authors:  R A Koup; J T Safrit; Y Cao; C A Andrews; G McLeod; W Borkowsky; C Farthing; D D Ho
Journal:  J Virol       Date:  1994-07       Impact factor: 5.103

8.  Autologous and heterologous neutralizing antibody responses following initial seroconversion in human immunodeficiency virus type 1-infected individuals.

Authors:  C Moog; H J Fleury; I Pellegrin; A Kirn; A M Aubertin
Journal:  J Virol       Date:  1997-05       Impact factor: 5.103

9.  Detection of CD4+ T cells harboring human immunodeficiency virus type 1 DNA by flow cytometry using simultaneous immunophenotyping and PCR-driven in situ hybridization: evidence of epitope masking of the CD4 cell surface molecule in vivo.

Authors:  B K Patterson; C Goolsby; V Hodara; K L Lohman; S M Wolinsky
Journal:  J Virol       Date:  1995-07       Impact factor: 5.103

10.  Development of a neutralizing antibody response during acute primary human immunodeficiency virus type 1 infection and the emergence of antigenic variants.

Authors:  J Lewis; P Balfe; C Arnold; S Kaye; R S Tedder; J A McKeating
Journal:  J Virol       Date:  1998-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.